Pozen appoints Dr Tomas Bocanegra head of development
This article was originally published in Scrip
Pozen has appointed Dr Tomas Bocanegra executive vice-president of development, responsible for driving all product development activities beginning with the company's lead pipeline candidate, PA32540 (aspirin and omeprazole), for myocardial infarction. Prior to joining Pozen, Dr Bocanegra served as senior vice-president of development at Daiichi Sankyo Pharma Development.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.